Patents by Inventor Jitinder WILKHU

Jitinder WILKHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11426362
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: August 30, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Publication number: 20220233495
    Abstract: The present invention relates to a pharmaceutical formulation containing one or more cannabinoids. Preferably the formulation is a molecular dispersion of one or more cannabinoids in a pH dependent release polymer. Preferably the formulation is able to target delivery of the cannabinoids to specific areas of the digestive system such as the colon or intestines.
    Type: Application
    Filed: May 28, 2020
    Publication date: July 28, 2022
    Inventors: Alan SILCOCK, Jitinder WILKHU
  • Publication number: 20220211629
    Abstract: The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.
    Type: Application
    Filed: August 19, 2021
    Publication date: July 7, 2022
    Inventors: Jitinder WILKHU, Alan SILCOCK
  • Publication number: 20220096397
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Stephen WRIGHT, Jitinder Wilkhu
  • Patent number: 11229612
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 25, 2022
    Assignee: GW Research Limited
    Inventors: Stephen Wright, Jitinder Wilkhu
  • Patent number: 11160757
    Abstract: The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer. In embodiments, the one or more cannabinoids are present in an amount ranging from 10% w/w to about 50% w/w. In embodiments, the pH dependent release polymer is present in an amount ranging from ranging from about 5% w/w to about 85% w/w.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: November 2, 2021
    Assignee: GW Research Limited
    Inventors: Jitinder Wilkhu, Alan Silcock
  • Publication number: 20210059949
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, or pharmaceutical composition, comprising a pharmaceutical formulation based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The oral pharmaceutical composition comprises a pharmaceutical formulation and at least one modified-release agent. By Type IV-like, it is meant that the pharmaceutical formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER, Mathew COLLINS
  • Publication number: 20210059976
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation comprises a combination of at least two cannabinoids. The first cannabinoid is selected from the group consisting of tetrahydrocannabinol (THC) and analogues thereof; and the second cannabinoid is selected from the group consisting of cannabidiol (CBD) and analogues thereof.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER
  • Publication number: 20210059960
    Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Inventors: Jitinder WILKHU, Johan BENDER
  • Publication number: 20190365667
    Abstract: The present invention relates to an oral formulation containing one or more cannabinoids. Preferably one or more cannabinoids dissolved in a solvent system consisting essentially of: a non-ionic surfactant and water together with other components which ensure the cannabinoids stability and the formulations palatability. Furthermore, the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: February 15, 2018
    Publication date: December 5, 2019
    Inventors: Stephen WRIGHT, Jitinder WILKHU
  • Publication number: 20190314296
    Abstract: The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).
    Type: Application
    Filed: June 29, 2017
    Publication date: October 17, 2019
    Inventors: Stephen Wright, Jitinder WILKHU
  • Publication number: 20180071210
    Abstract: The present invention relates to an oral pharmaceutical formulation comprising a cannabinoid. The formulation may take the form of a mucoadhesive gel, a tablet, a powder, a liquid gel capsule, an oral solution, granules, extrudates or injectable.
    Type: Application
    Filed: June 30, 2017
    Publication date: March 15, 2018
    Inventors: Jitinder WILKHU, Johan BENDER